Haploidentical Hematopoietic Stem Cell Transplantation With Anti-Thymocyte Globulin in the Treatment of Older Adults With Hematological Malignancy.

Key Points

• The central aim is to evaluate the safety and efficacy of haploidentical hematopoietic stem cell transplantation with anti-thymocyte globulin in older adults.
• Conducted a trial evaluating treatment outcomes in patients aged 60 and older.
• Administered haploidentical stem cell transplantation with anti-thymocyte globulin.
• Monitored safety and efficacy outcomes over a determined follow-up period.
• Haploidentical SCT with ATG is found to be safe for patients aged ≥ 60 years.
• The treatment shows promising efficacy in managing hematological malignancies.